Trump’s New Drug Price Order May Help Indian Medicine Companies

U.S. President Donald Trump recently signed an order to lower drug prices in the United States. His plan is to make sure Americans don’t pay more for medicine than people in other rich countries. Many people in the U.S. currently pay much higher prices for the same drugs that are cheaper in other countries.

This order mainly targets expensive, brand-name medicines made by big American drug companies, often called “Big Pharma.” These include companies like Pfizer and Merck. But the order is not expected to hurt Indian companies that make generic (non-brand) drugs.

Indian drugmakers sell generic medicines at very low prices and already supply a large portion of the U.S. market. In fact, about 90% of all prescriptions in the U.S. are filled with generic drugs, and many of these come from India.

Experts say this move by the U.S. government may actually benefit Indian pharmaceutical companies. Since Indian drugs are already low-cost, they probably won’t need to reduce their prices further. Also, if American companies try to save money by cutting research costs, they might hire Indian companies to do that work at a lower price.

Business leaders like Kiran Mazumdar-Shaw, head of Biocon, believe this could open new doors for Indian companies to take on more global contracts for research and production.

Some people are still waiting to see exactly how the U.S. government will apply the new pricing rules. But for now, it looks like Indian medicine companies may gain an advantage, not lose one.

In short, Trump’s decision to lower drug prices in the U.S. could help Indian generic drug makers, who already offer affordable medicine and may now find more business opportunities globally.